Trial · NCT00185900
Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial
NCT00185900, Not applicable, Completed, Stanford University; results first posted 2018-10-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial. Trials, record NCT00185900. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00185900
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial
- NCT number
- NCT00185900
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 192 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Obstetric Labor, Premature
- Interventions
- Magnesium Sulfate, Nifedipine
- First posted
- 2005-09-16
- Last updated
- 2018-11-19
- Results first posted
- 2018-10-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence | 48 hours after administration of study medication. | Uterine quiescence defined by 12 hours of six or fewer contractions per hour and no further cervical change within 48 hours of tocolytic initiation. |
| Secondary | Time to Uterine Quiescence | Until delivery, up to 42 weeks of gestation | Uterine quiescence was defined by 12 hours of six of fewer contractions per hour and no further cervical change. |
| Secondary | Gestational Age at Delivery | Until delivery, up to 42 weeks of gestation | Presented as weeks |
| Secondary | Neonatal Birth Weight | Until delivery, up to 42 weeks of gestation | Presented as grams |
| Secondary | Serious Maternal Adverse Effect | From study enrollment until discharge from delivery hospital, up to 30 days after delivery. | A composite of any of the following: chest pain, pulmonary edema, shortness of breath or hypotension. |
| Secondary | Composite Neonatal Morbidity | From delivery until discharge from the hospital, up to 30 days of age | Defined as any of the following: respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis or fetal/neonatal death. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence | 48 hours after administration of study medication. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Uterine Quiescence | Until delivery, up to 42 weeks of gestation | hours | MEAN | |
| SECONDARY | Gestational Age at Delivery | Until delivery, up to 42 weeks of gestation | weeks | MEAN | |
| SECONDARY | Neonatal Birth Weight | Until delivery, up to 42 weeks of gestation | Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed | grams | MEAN |
| SECONDARY | Serious Maternal Adverse Effect | From study enrollment until discharge from delivery hospital, up to 30 days after delivery. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Composite Neonatal Morbidity | From delivery until discharge from the hospital, up to 30 days of age | Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence | Magnesium Sulfate | 80 | Participants | ||
| Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence | Nifedipine | 72 | Participants | ||
| Time to Uterine Quiescence | Magnesium Sulfate | 8.4 | Standard Deviation 6.5 | hours | |
| Time to Uterine Quiescence | Nifedipine | 6.1 | Standard Deviation 6.3 | hours | |
| Gestational Age at Delivery | Magnesium Sulfate | 35.8 | Standard Deviation 3.4 | weeks | |
| Gestational Age at Delivery | Nifedipine | 36.0 | Standard Deviation 3.1 | weeks | |
| Neonatal Birth Weight | Magnesium Sulfate | 2550 | Standard Deviation 802 | grams | |
| Neonatal Birth Weight | Nifedipine | 2650 | Standard Deviation 698 | grams | |
| Serious Maternal Adverse Effect | Magnesium Sulfate | 20 | Participants | ||
| Serious Maternal Adverse Effect | Nifedipine | 10 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Magnesium Sulfate | 92 | |
| Overall Study | STARTED | Nifedipine | 100 | |
| Overall Study | COMPLETED | Magnesium Sulfate | 92 | |
| Overall Study | COMPLETED | Nifedipine | 100 | |
| Overall Study | NOT COMPLETED | Magnesium Sulfate | 0 | |
| Overall Study | NOT COMPLETED | Nifedipine | 0 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Magnesium Sulfate | 29 | 92 | |
| other | Nausea | Gastrointestinal disorders | Nifedipine | 6 | 100 | |
| other | Lethargy | Nervous system disorders | Magnesium Sulfate | 27 | 92 | |
| other | Lethargy | Nervous system disorders | Nifedipine | 3 | 100 | |
| other | Vomiting | Gastrointestinal disorders | Magnesium Sulfate | 24 | 92 | |
| other | Vomiting | Gastrointestinal disorders | Nifedipine | 5 | 100 | |
| other | Flushing | Skin and subcutaneous tissue disorders | Magnesium Sulfate | 20 | 92 | |
| other | Flushing | Skin and subcutaneous tissue disorders | Nifedipine | 1 | 100 | |
| other | Blurry Vision | Eye disorders | Magnesium Sulfate | 12 | 92 | |
| other | Blurry Vision | Eye disorders | Nifedipine | 0 | 100 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Magnesium Sulfate | 0 | 92 |
| Total, all-cause mortality | Nifedipine | 0 | 100 |
| Total, other adverse events | Magnesium Sulfate | 29 | 92 |
| Total, other adverse events | Nifedipine | 22 | 100 |
| Total, serious adverse events | Magnesium Sulfate | 25 | 92 |
| Total, serious adverse events | Nifedipine | 12 | 100 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Magnesium Sulfate vs Nifedipine: Serious Maternal Adverse Effect | Trial comparisons |
| Magnesium Sulfate vs Nifedipine: Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence | Trial comparisons |
| Magnesium Sulfate vs Nifedipine: Composite Neonatal Morbidity | Trial comparisons |
| Magnesium Sulfate vs Nifedipine: deaths from any cause | Trial comparisons |
| Magnesium Sulfate vs Nifedipine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00185900
GET https://conductscience.org/api/trials/v1/NCT00185900/events?page=2